Clorox Company (CLX) has been making waves in the biotech market with various developments. Financial commentator,
Jim Cramer, has highlighted the company's consistency, while it also garnered a higher rating from Wall Street Zen to "Hold". Q2 results revealed misses on EPS estimates, but
strong strategic innovation and growth plans offered some optimism. However, its stock valuation has declined, but some positive forecasts come from TD Cowen and Citigroup. It recently acquired
GOJO Industries, makers of
Purell, indicating a significant move towards skin health and hygiene. Unfortunately, Clorox's stock has hit an 11-year low, despite this significant acquisition and expansion into sanitizing solutions. The company continues to face challenges, such as declining sales volume and EPS misses, but maintains solid strategies to navigate these areas. Astonishingly, even with looming uncertainties, Clorox expands partnership with Realize the Dream to offer global employee volunteer service. Nevertheless, concerns for the company remain, such as cost headwinds and fundamentals concerns from Barclays.
Clorox Company CLX News Analytics from Mon, 21 Jul 2025 07:00:00 GMT to Sat, 07 Feb 2026 16:51:27 GMT -
Rating -3
- Innovation 5
- Information 7
- Rumor -2
